High prevalence of echocardiographic abnormalities in older HIV-infected children taking antiretroviral therapy

Edith D MAJONGA 1,2, Andrea M REHMAN 1, Victoria SIMMS 1, Grace MCHUGH 2, Hilda A MUJURU 3, Kusum NATHOO 3, Jon O ODLAND 4,5, Mohammad S PATEL 6, Juan P KASKI 7,8,*, Rashida A FERRAND 1,2

1 London School of Hygiene and Tropical Medicine, London, United Kingdom; 2 Biomedical Research and Training Institute, Harare, Zimbabwe; 3 University of Zimbabwe, Harare, Zimbabwe; 4 UiT The Arctic University of Norway, Tromsø, Norway; 5 Department of Public Health, University of Pretoria, South Africa; 6MRI & Radiology Centre, Harare, Zimbabwe; 7 Centre for Inherited Cardiovascular Diseases, Great Ormond Street Hospital, London, United Kingdom; 8 Institute of Cardiovascular Science, University College London, United Kingdom; * Member of the European Reference Network on Heart Diseases (ERN GUARD-HEART)

Corresponding Author:
Edith D Majonga
Clinical Research Department
London School of Hygiene and Tropical Medicine
Keppel Street
London WC1E 7HT, United Kingdom
Email: Edith.Majonga@lshtm.ac.uk Tel: +44 207 927 2577

Short title: Cardiac abnormalities in children on ART

Key words: cardiac abnormalities, HIV, children, ART, Africa

Word count: 3609
Funding

This work was funded by the Wellcome Trust (095878/Z/11/Z). Salary support for AMR was provided by the UK Medical Research Council through a grant to the LSHTM Tropical Epidemiology Group; grant code MR/K012126/1.
Introduction

Of the approximately 3.2 million children with HIV globally, 90% live in sub-Saharan Africa.[1] The global expansion of prevention of mother-to-child HIV transmission and scale up of antiretroviral therapy (ART) programs has resulted in a substantial decrease in the number of infants born with HIV and an increase in numbers of older children and adolescents living with HIV due to improved survival on ART.[2]

While ART has dramatically decreased the risk of opportunistic infections and mortality, there is mounting evidence that longstanding HIV infection and/or its treatment are associated with non-infectious complications, including cardiac disease.[3] Cardiac disease has been reported among treated and untreated HIV-infected adults, with prevalence ranging from 18-78%.[4, 5] Low CD4 cell count and high viral load have been identified as independent risk factors for cardiac disease, but residual confounding by well-recognised traditional risk factors such as smoking and hypertension remain an issue in these studies.[5] A small number of studies have suggested that children with HIV also are at risk of cardiac disease, despite the absence of traditional risk factors, with the most common reported abnormalities being left ventricular (LV) dilatation and systolic dysfunction.[6, 7] HIV infection can also lead to right heart abnormalities, either as a consequence of pulmonary arterial hypertension (PAH) or secondary to chronic lung disease.

We have previously reported a high prevalence of chronic lung disease among HIV-infected older children on ART[8, 9], which may result in pulmonary hypertension and subsequent right ventricular (RV) dilatation and/or RV systolic dysfunction.[10] However, most studies were conducted in children on zidovudine monotherapy or in mixed cohorts of ART-naive and experienced participants, and were mainly performed in younger children in high-resource settings.[7, 11]

In the ART era, there are contrasting reports on cardiac disease in HIV-infected children who are on ART from high and low-resource settings.[12-14] We therefore investigated the prevalence, spectrum and risk factors for cardiac abnormalities in children established on ART in Harare, Zimbabwe.
**Methods**

A cross-sectional study was conducted at the pediatric HIV clinic at Harare Central Hospital, Zimbabwe, between August 2014 and June 2015. Harare Central Hospital is the largest public-sector hospital in Harare and provides HIV care to over 4000 children. This study was conducted within a larger cohort study called INHALE (Investigation of Heart and Lung Diseases in HIV among older children), aiming to investigate cardiorespiratory disease in children with HIV infection. Findings of the clinical and radiographic features of chronic lung disease have already been published.[8, 9] This report is limited to echocardiographic abnormalities in the same cohort of HIV-infected children.

HIV-infected children aged 6-16 years attending for HIV care, not acutely ill and taking ART for at least six months, were consecutively recruited on week days, restricted to the first five eligible participants per day for logistical ease. A minimum of 6 months on ART was selected to enable sufficient time for viral suppression and for the risk of immune reconstitution syndrome to have dropped.

**Study procedures**

An interviewer-administered questionnaire was used to collect socio-demographic data and clinical history, including previous illnesses, drug history and current symptoms. A standardized clinical assessment was performed, including anthropometric measurement (height and weight), heart rate, respiratory rate, blood pressure, New York Heart Association (NYHA) functional class, pulse oximetry and Medical Research Council (MRC) Dyspnoea scale. Fasted blood was collected for measurement of plasma glucose, and for HIV-1 viral load and CD4 count testing. The CD4 count was measured on site using an Alere PIMA analyser (Alere Technologies GmbH, Jena, German) and plasma VL was measured using the COBAS protocol Ampliprep/Taqman 48 Version 2.0 (Roche Molecular System, Branchburg, USA). Spirometry was performed according to American Thoracic Society guidelines to assess respiratory function.[15]

A transthoracic echocardiogram was performed using a Mindray DC N6 multipurpose ultrasound machine (Mindray, Shenzhen, China) by an echocardiographer trained in pediatric echocardiography (EM). A
standard protocol consisting of 2-dimensional, M-mode, pulsed and continuous wave Doppler and colour flow mapping as recommended for transthoracic echocardiography was adopted [16]. Participants were scanned in the left lateral or supine position to obtain an optimum image quality and all measurements made over three cardiac cycles. Images were acquired using a 7MHz transducer and were saved in DICOM format for off-line analysis. Cardiac measurements were based on the American Society of Echocardiography (ASE) criteria [16]. Echocardiography scans were quality controlled by an experienced pediatric cardiologist (JPK) for adequacy of views. Furthermore, a random sample of 10% scans were re-measured by an independent rater (MSP) for interobserver agreement.

**Definitions**

Echocardiography measures for LV and right ventricular (RV) dimensions were normalized to body surface area calculated using Du Bois and Du Bois formula,[17] and converted to z-scores using local references[18] and further compared to European published references among Caucasian children.[19] Local reference ranges were used as the primary basis for defining cardiac abnormalities in the study. LV and RV dilatation were defined as a z-score >+2 for LV and RV diameter in diastole respectively, left atrial dilatation was a z-score >+2 for left atrial diameter in systole and LVH was defined as maximal wall thickness of interventricular septum and/or LV posterior wall greater than +2 z-scores.[18] LV systolic function was assessed by Simpson’s Biplane method and an ejection fraction ≥ 55% was considered normal.[16] LV diastolic dysfunction was assessed through transmitral Doppler (peak early (E) and late diastolic (A) filling velocities), E/A ratio, deceleration time and pulmonary venous flow velocities including peak systolic (S) and diastolic (D) waves, S/D ratio and atrial reversal (Ar) velocity and paediatric reference ranges were used to define abnormality.[20] Patients were classified as having diastolic dysfunction when at least four parameters were abnormal.[21] RV systolic dysfunction was defined as a tricuspid annular plane systolic excursion (TAPSE) z-score of <−2.[18] Pulmonary hypertension was defined as present if the tricuspid regurgitation velocity was ≥2.9 m/s, estimated pulmonary arterial systolic pressure (PASP) ≥37 mmHg with/without additional echocardiographic variables suggestive of pulmonary hypertension.
PASP was indirectly calculated from the pressure gradient across the tricuspid valve (TV) by measuring the regurgitant jet and applying the simplified Bernoulli equation \((4V^2)\) and adding right atrial pressure (RAP) estimate to the tricuspid pressure gradient.[22] Hypoxia was defined as a resting oxygen saturation <88% or a ≥5% desaturation immediately following exercise; resting tachypnea was defined as a respiratory rate >25/min. Sinus tachycardia was defined as >130 beats per minute (bpm) for children aged 6-8 years and >110bpm for those aged 9-16 years.[23] Stunting and wasting were defined as a z-score < -2 for height-for-age and weight-for-age respectively, using British 1990 growth references.[24] Hypertension was defined as the systolic blood pressure and/or diastolic blood pressure ≥ 95th percentile; prehypertension was systolic blood pressure and/or diastolic blood pressure between the 90th and 95th percentile for age, gender and height.[25] Chronic lung disease was defined as having at least one of the following criteria: chronic cough (≥ 3 months) with tuberculosis excluded; hypoxia (SpO₂ <90% or desaturation ≥5% upon exertion); abnormal spirometry (defined as reduced ratio of the highest forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) (FEV1: FVC) or reduced FVC regardless of normal FEV1: FVC ratio) irreversible with salbutamol[9] and MRC Dyspnoea scale >1.[26]

**Data management and statistical analysis**

Data were extracted from paper forms using optical character recognition software (Cardiff TELEFORM Intelligent Character, Version 10.7). Data were analyzed using STATA version 12 software (StataCorp, Texas, USA).

A previous, retrospective, cross-sectional study in Zimbabwean adolescents found the prevalence of cardiac abnormalities to be between 24% and 67%.[27] We calculated a sample size of 200 was required to estimate an assumed prevalence of 65% with a precision of +/- 8% to 10%, for a 95% confidence interval. The association between HIV-related and clinical factors, determined a priori, and left and right cardiac abnormalities was investigated using multivariate logistic regression and odds ratios were calculated. Age and sex were included as a priori variables. HIV-related factors were categorized as follows: CD4 count
(>200 cells/μL and ≤200 cells/μL), HIV viral load (≤400 copies/ml and >400 copies/ml), age at ART initiation (0-5, 6-10 and 11-16 years), duration on ART (≤2 years and >2 years) and age was categorized as 6-10 years and 11-16 years. Antiretroviral drugs (ARVs), cardiac signs and symptoms, hypertension and chronic lung disease were dichotomized into yes and no. Zidovudine and nevirapine were selected because of evidence that zidovudine is associated with development of cardiomyopathy in children and nevirapine is associated with LVH in adults.[28, 29] Clinical factors evaluated include cardiac signs and symptoms, hypertension and chronic lung disease. Cardiac signs and symptoms included hypoxia, chest pains, tachypnoea and ankle swelling, and were grouped into one variable called cardiac symptoms. HIV-related variables that were significant at p≤0.1 on univariate logistic regression analysis were included in a multivariate logistic regression model. Clinical variables were added to the model and any clinical variable that was significant at p≤0.1 was retained for inclusion in the final model. A value of p≤0.05 was considered statistically significant in the final model. Intra- and interobserver agreement was assessed through Bland-Altman plots.[30] Variability was estimated by calculating the mean (95% CI) of the arithmetic differences between repeated cardiac measures of the same participant. Normally distributed differences would fall within a range of mean ±1.96SD and the range is referred to as limits of agreement (LoA).

Ethical approval was obtained from the Medical Research Council of Zimbabwe, the London School of Hygiene and Tropical Medicine Ethics Committee, the Biomedical Research and Training Institute Institutional Review Board and the Harare Central Hospital Ethics Committee. Written informed consent from guardians and assent from participants was obtained prior to enrolment. Any abnormal findings during the course of the study were recorded in the child’s notes and the child was referred to a clinician on the same day for further management.

Results

Clinical characteristics
Of the 921 attendees to the clinic aged 6-16 years over the study period, 397 were eligible and of these, 201 children were enrolled; the remainder were excluded due to the total number of enrolments being restricted to the first five eligible attendees per day (Figure 1). The median age was 11.1 years (IQR, 9-12) and 92 (46%) were female. Mother-to-child transmission was assessed as the likely mode of HIV acquisition in all but one participant, in whom we speculate that HIV had been acquired through sexual transmission because the mother had tested HIV negative when the child was diagnosed at the age of 6 years. Participants were taking ART for a median duration of 4.7 years (IQR, 2.6-6.4) and 154/197 (78%) had an HIV VL<400 copies/ml; the median CD4 count at enrolment was 727 cell/μl (IQR, 473-935) (n=198). No participant was taking any medication for cardiac disease. Eligible children who were not enrolled in the study were on average 5 months younger than those enrolled and had initiated ART at a year younger (Supplementary Table 1).

Thirty-four (17%) children had a history of chest pain, 36/201 (18%) were in NYHA functional class >1 and 24/198 (12%) had hypoxia. An abnormal blood pressure was observed in 106/198 (54%) children: 85/106 (80%) had hypertension and 21/106 (20%) had prehypertension. Chronic cough was reported in 30 (15%) and dyspnoea using the MRC dyspnoea scale in 30 (15%) and 42 (24%) had abnormal lung function on spirometry (Table 1).

**Echocardiographic findings**

Of the 201 enrolled participants, echocardiograms were performed on 197; the remaining four did not return for the examination. Echocardiographic measures are summarized in Table 2. Eighty-three (42%) participants had an echocardiographic abnormality of either the left and/or right heart. The most common abnormal finding was LV diastolic dysfunction in 45/197 (23%) children (Table 3). Isolated diastolic dysfunction, without associated LV dilatation or LVH, was observed in 33/45 (73%) children. LVH was the second most common finding in 22/197 (11%) with the following patterns: interventricular septal hypertrophy 2/22 (9%) and posterior wall hypertrophy 20/22 (91%). Seven children (32%) with LVH had diastolic dysfunction and global systolic function was impaired in one child. LV dilatation was observed in
9/197 (5%) children, one of whom had impaired systolic function and pericardial effusion. Left atrial dilatation was found in 16/197 (8%) children and of these 4 (25%) had LVH; 4 (25%) had diastolic dysfunction; and 2 (12%) had LV dilatation.

RV dilatation was found in 13/197 (7%) and RV systolic dysfunction in 4/180 (2%) including two children with both RV dilatation and systolic dysfunction. Of the 15 participants who had RV abnormalities, nine (60%) had concurrent left heart abnormalities, including isolated LVH (n=2), isolated LV dilatation (n=1), isolated Left atrial dilatation (n=1), LV systolic dysfunction and LVH (n=1), isolated LV diastolic dysfunction (n=3) and one participant who had a dilated cardiomyopathy with LV and Left atrial dilatation and LV systolic dysfunction. Five (33%) of the participants with right heart abnormalities also met the case definition for chronic lung disease. None of the participants met the echocardiographic criteria for pulmonary hypertension. The prevalence of echocardiographic abnormalities was much higher when European reference ranges were used (Table 3).

Twenty (10%) echocardiograms were used to determine inter-observer agreement. Bland-Altman plots showed that there was good agreement for repeated measures by the same observer two weeks apart and repeated measures between the two observers (Figure S1).

**Factors associated with echocardiographic abnormalities**

LV diastolic dysfunction was associated with hypertension (aOR 3.12 (1.48-6.57; p<0.01). Hypertension and LV diastolic dysfunction were present in 33/45 (73%) of the participants. LVH was associated with current use of nevirapine (aOR 3.14 (1.13-8.72; p=0.03) (Table 4). No HIV-related factors nor symptoms were associated with left atrial dilation. No associations were found between RV abnormalities and HIV-related factors including CD4 count, viral load, duration on ART, age at ART initiation and lung function (supplementary Table 2).
Discussion

This study demonstrates a high prevalence of echocardiographic abnormalities among HIV-infected children established on ART, more than three-quarters of whom were virologically suppressed. Most of the participants with diastolic dysfunction had preserved systolic function. LV diastolic dysfunction is well described in adults with HIV but there are limited data on diastolic dysfunction in children. Diastolic parameters are difficult to measure in children and very slight alterations can result in significant changes in interpretation of the diastolic function. Interestingly, in the pre-ART era, systolic dysfunction and LV dilatation rather than impaired LV diastolic function were the predominant abnormalities observed, suggesting that LV diastolic impairment may be an earlier manifestation of cardiac disease.[31] It is not uncommon for diastolic dysfunction to present in isolation, typically before systolic impairment becomes apparent, for example in ischaemic cardiomyopathy.[32]

Among those with LVH, LV posterior wall thickening was predominant, in keeping with our previous report.[27] Idris and colleagues found that children with HIV and exposed to ART had thicker LV posterior walls compared to ART- naïve children and larger LV dimensions compared to uninfected children.[33] LV dilatation was less common than LVH in our study. We found that current use of nevirapine was associated with LVH, which may suggest possible treatment induced effect on the myocardium. Nevirapine has been associated with LVH among HIV infected adults in Spain, most of whom were on ART and virally suppressed.[28]

An important, previously unreported, abnormality found in our study was Left atrial dilatation, which is associated with adverse clinical outcomes such as atrial fibrillation and all-cause mortality in a range of cardiac disease, including ischaemic heart disease and hypertrophic cardiomyopathy.[34] Left atrial dilatation may occur because of increased LV filling pressures in the context of impaired LV diastolic function, for example among those with LVH, or because of LV dilatation.[34] Our data suggest that, in this population, Left atrial dilatation is related to the former. Further studies are required to investigate
whether Left atrial dilatation also represents a marker of increased risk of mortality among individuals living with HIV.

More than half of the children had strikingly high blood pressure, but no association was found between LVH and abnormal blood pressure. However, we did find that LV diastolic dysfunction was associated with elevated blood pressure; hypertension is an established risk factor for LV diastolic dysfunction and a major contributor of heart disease.[35] However, not all patients with diastolic dysfunction had hypertension, suggesting a possible additional primary myocardial aetiology. Chatterton-Kirchmeier and colleagues also reported a high prevalence of elevated blood pressure among HIV-infected children and adolescents (age range 2-17 years), most of whom were on ART.[36] The reasons for this remain unclear, but this finding merits further investigation in this population. A high prevalence of elevated blood pressure in African children has been previously reported, in keeping with the present study.[37-40] There is a possibility of misclassification of participants as hypertensive; although we used the Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents, we did not perform repeated measures of BP for our participants on separate visits.[25] Furthermore, there may have been an element of “white coat hypertension”. Another explanation could be the possibility that the definition used for hypertension in this study, which is derived from reference ranges obtained from 70,000 children and adolescents from USA, is not suitable for the population under study.[25] Currently, there are no blood pressure references for African children.

We found RV abnormalities (dilatation and systolic dysfunction) in 8% of the children. RV dilatation was the most common right sided abnormality, although lower than the 29% previously reported among Zimbabwean perinatally HIV-infected adolescents.[27] The former study enrolled older children aged between 10-19 years and included both ART naïve and ART-experienced children. Chelo and colleagues reported an even higher prevalence of RV dilatation (76%) among Cameroonian children aged 1–15 years, 91% of whom were on ART. The Zimbabwean study used European children’s references by Kampmann et al.[19] and the Cameroonian study used adults’ references as recommended by the ASE[41], and it is
possible that the prevalence of RV dilatation may have been overestimated in both studies. A comparison of African reference ranges, derived from Zimbabwean HIV-uninfected children and the European references by Kampmann et al.[19] and Huwez et al.[42] showed that RV diameters are higher among Black African children.[18] In this study we used locally developed reference ranges as a control population to define echocardiographic abnormalities.[18] European echocardiographic references derived from Caucasians[19] over-estimated the prevalence of some abnormalities in our cohort, underscoring the importance of using local reference ranges. Western reference ranges may not be appropriate and may explain the differences in prevalence of cardiac disease with the present study.

We did not find any association between RV abnormalities and chronic lung disease or other HIV related factors and this may be due to a lack of power to detect the associations. More than half of the children with RV abnormalities had left heart abnormalities too, suggesting that the abnormalities in the right heart may be part of a global cardiomyopathic process. RV impairment may be secondary to left-sided cardiomyopathy and several mechanisms have been postulated, including the possibility that the same cardiomyopathic process may affect both ventricles. Alternatively, LV failure may result in reduced coronary perfusion for both LV and RV, or the dilated LV may cause RV diastolic dysfunction due to cumulative pericardial limitation.[43]

Most of the children in our study had normal RV systolic function despite having RV dilatation. Ventricular dilatation commonly occurs as an early structural change to maintain stroke volume when there is reduced wall motion.[44] It is possible that ventricular systolic dysfunction was subclinical and would clinically manifest over time.[45]

None of the children had elevated PASP in our study, using Doppler echocardiography. Although Doppler echocardiography is recognised as an important tool for screening and assessment of patients at risk of pulmonary hypertension[46], right heart catheterisation is the gold standard in diagnosis of pulmonary hypertension, and recent reports have shown that Doppler echocardiography may under- or over-estimate pulmonary pressures, especially in children with elevated right heart pressures.[47] It is possible, therefore,
that right heart pressures may have been underestimated in our study. However, the concurrent right and left heart abnormalities in some of the children suggest that the observed RV abnormalities are not related to undiagnosed pulmonary hypertension but, rather, may reflect an underlying biventricular cardiomyopathic process. Further studies are required to investigate this.

Although one fifth of the children reported one or more cardiac symptoms, most children with cardiac abnormalities were asymptomatic. These findings highlight the importance of regular cardiac screening in this population, even in the absence of symptoms. Myocardial disease is often subclinical and may only become symptomatic once it progresses and leads to significant cardiac dysfunction. Relying on symptoms alone without echocardiography screening may therefore result in delayed diagnosis of cardiac disease.

Pathogenesis of cardiac disease in HIV infection is likely multifactorial. HIV causes dysregulated systemic activation which leads to chronic inflammation. These mechanisms contribute to organ damage. Furthermore, damage to the immune system before subsequent access to ART maybe responsible for this long-term effect of cardiac abnormalities. Although the children in this study were stable on ART with high CD4 count and virally suppressed at the time of the study, low nadir CD4 count and/or opportunistic infections may have occurred and contributed to cardiac damage. Cardiotropic viruses including cytomegalovirus, coxsackievirus and Epstein-Barr virus have been reported to cause cardiac dysfunction in HIV [48] although we did not investigate presence of these viruses in these children. Deficiency of trace elements such as selenium have also been associated with HIV-associated cardiomyopathy,[49] but were not measured in this study.

A major strength of this study was the systematic cardiological assessment, with echocardiography performed prospectively by a pediatric echocardiographer. Most importantly, we used local echocardiography reference ranges to define cardiac abnormalities.[18] Participants were not recruited selectively based on symptoms. Our study is limited by lack of data on global LV longitudinal strain, which may have been more sensitive to detecting subclinical LV systolic dysfunction, not apparent in the form of reduced LV ejection fraction. It is also limited by lack of a control group, but all cardiac abnormalities were
defined using reference measures derived locally. Local reference ranges were however, not available for blood pressure. Hyperlipidemia is a recognized risk factor for cardiac disease, but we were unable to assess lipid profiles due to resource constraints. The children in this study did not undergo routine blood hemoglobin testing, although there was no clinical suspicion of anemia. The study is cross-sectional and may have been underpowered to detect any associations between risk factors and cardiac abnormalities. Due to the cross-sectional design, no causality can be attributed to the factors that were associated with cardiac abnormalities.

In conclusion, our study demonstrates that there is a high burden of echocardiographic abnormalities in children, despite good control of HIV infection with ART. Our findings also suggest that right heart abnormalities in HIV-infected children on ART appear to be associated with abnormalities of the left heart. The impact and clinical course of these abnormalities and potential for reversibility still need to be investigated in prospective longitudinal studies. Further study of the pathogenesis of cardiac abnormalities will inform development of appropriate screening and therapeutic strategies for an increasing number of children growing up with HIV who face the prospect of taking lifelong ART.

**Acknowledgments**

We would like to thank Harare Children’s Hospital, the clinic staff, participants and their families.
References

1. **UNAIDS THE GAP REPORT.**
   [http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Gap_report_en.pdf](http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Gap_report_en.pdf) (2014; 21 Aug 2016)
2. **UNAIDS.** How AIDS changed everything – MDG6: 15 years, 15 lessons of hope from the AIDS response.
   [http://www.unaids.org/sites/default/files/media_asset/MDG6Report_en.pdf](http://www.unaids.org/sites/default/files/media_asset/MDG6Report_en.pdf) (27 August 2016)
3. Lowenthal ED, Bakeera-Kitaka S, Chapman J, Goldrath K, Ferrand RA. Perinatally acquired HIV infection in adolescents from sub-Saharan Africa: a review of emerging challenges. *The Lancet Infectious Diseases* 2014; 14:627-39
4. Olusegun-Joseph DA, Ajuluchukwu JN, Okany CC, Mbakwem AC, Oke DA, Okubadejo NU. Echocardiographic patterns in treatment-naive HIV-positive patients in Lagos, south-west Nigeria. *Cardiovasc Journal of Afr* 2012; 23:e1-6
5. Twagirumukiza M, Nkeramihigo E, Seminega B, Gasakure E, Boccara F, Barbaro G. Prevalence of dilated cardiomyopathy in HIV-infected African patients not receiving HAART: a multicenter, observational, prospective, cohort study in Rwanda. *Current HIV Research* 2007; 5:129-37
6. Starc TJ, Lipshultz SE, Kaplan S, Easley KA, Bricker JT, Colan SD, *et al.* Cardiac complications in children with human immunodeficiency virus infection. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group, National Heart, Lung, and Blood Institute. *Pediatrics* 1999; 104:e14
7. Lipshultz SE, Easley KA, Orav EJ, Kaplan S, Starc TJ, Bricker JT, *et al.* Left Ventricular Structure and Function in Children Infected With Human Immunodeficiency Virus: The Prospective P2C2 HIV Multicenter Study. *Circulation* 1998; 97:1246-56
8. Desai SR, Nair A, Rylance J, Mujuru H, Nathoo K, McHugh G, *et al.* HIV-Associated Chronic Lung Disease in Children and Adolescents in Zimbabwe: Chest Radiographic and High-Resolution Computed Tomography Findings. *Clinical Infectious Diseases* 2017:cix778-cix
9. Rylance J, McHugh G, Metcalf J, Mujuru H, Nathoo K, Wilmore S, *et al.* Chronic lung disease in HIV-infected children established on antiretroviral therapy. *AIDS* 2016; 30:2795-803
10. Zangiabadi A, De Pasquale CG, Sajkov D. Pulmonary hypertension and right heart dysfunction in chronic lung disease. *Biomed Res Int* 2014; 2014:739674
11. Pongprot Y, Sittiwangkul R, Silvilairat S, Sirisanthana V. Cardiac manifestations in HIV-infected Thai children. *Ann Trop Paediatr* 2004; 24:153-9
12. Namuyonga J, Lubega S, Musiime V, Lwabi P, Lubega I. Cardiac Dysfunction Among Ugandan HIV-Infected Children on Antiretroviral Therapy. *Pediatr Infect Dis J* 2016;
13. Sainz T, Alvarez-Fuente M, Fernandez-Jimenez R, Gonzalez-Tome M, de Jose M, Ramos J, et al. Cardiac function in vertically HIV-infected children and adolescents in the era of highly active antiretroviral therapy. Pediatr Infect Dis J 2015; 34:e125-31
14. Chelo D, Wawo E, Siaha V, Anakeu A, Ndongo FA, Ndombo POK, et al. Cardiac anomalies in a group of HIV-infected children in a pediatric hospital: an echocardiographic study in Yaounde, Cameroon. Cardiovascular Diagnosis and Therapy 2015; 5:444-53
15. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. European Respiratory Journal 2005; 26:319-38
16. Lopez L, Colan SD, Frommelt PC, Ensing GJ, Kendall K, Younoszai AK, et al. Recommendations for quantification methods during the performance of a pediatric echocardiogram: a report from the Pediatric Measurements Writing Group of the American Society of Echocardiography Pediatric and Congenital Heart Disease Council. J Am Soc Echocardiogr 2010; 23:465-95; 576-7
17. Du Bois D, Du Bois, EF. A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition (Burbank, Los Angeles County, Calif) 1989; 5:303
18. Majonga ED, Rehman AM, McHugh G, Mujuru HA, Nathoo K, Patel MS, et al. Echocardiographic reference ranges in older children and adolescents in sub-Saharan Africa. International Journal of Cardiology 2017; 248:409-13
19. Kampmann C, Wiethoff CM, Wenzel A, Stolz G, Betancor M, Wippermann CF, et al. Normal values of M mode echocardiographic measurements of more than 2000 healthy infants and children in central Europe. Heart 2000; 83:667-72
20. O'Leary PW, Durongpisitkul K, Cordes TM, Bailey KR, Hagler DJ, Tajik J, et al. Diastolic ventricular function in children: a Doppler echocardiographic study establishing normal values and predictors of increased ventricular end-diastolic pressure. Mayo Clin Proc 1998; 73:616-28
21. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European Journal of Echocardiography 2016; 17:1321-60
22. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30:2493-537
23. Lennox EG. Cardiology. Arcara KM TM, eds. Johns Hopkins: The Harriet Lane Handbook.: PA: Mosby Elsevier Inc; 2012.
24. Cole TJ, Freeman JV, Preece MA. British 1990 growth reference centiles for weight, height, body mass index and head circumference fitted by maximum penalized likelihood. *Stat Med* 1998; 17:407-29
25. National Institutes of Health. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. *US Pediatrics* 2005; 114:55-76
26. Fletcher CM. Standardised questionnaire on respiratory symptoms: a statement prepared and approved by the MRC Committee on the Aetiology of Chronic Bronchitis (MRC breathlessness score). *British Medical Journal* 1960; 2:241–3
27. Miller RF, Kaski JP, Hakim J, Matenga J, Nathoo K, Munyati S, et al. Cardiac disease in adolescents with delayed diagnosis of vertically acquired HIV infection. *Clin Infect Dis* 2013; 56:576-82
28. Pombo M, Olalla J, Del A, Alfonso D, Javier U, Daniel A, et al. Left ventricular hypertrophy detected by echocardiography in HIV-infected patients. *European Journal of Internal Medicine* 2013; 24:558-61
29. Domanski MJ, Sloas MM, Follmann DA, Scalise PP, 3rd, Tucker EE, Egan D, et al. Effect of zidovudine and didanosine treatment on heart function in children infected with human immunodeficiency virus. *J Pediatr* 1995; 127:137-46
30. Bland JM, Altman D. Statistical methods for assessing agreement between two methods of clinical measurement. *The lancet* 1986; 327:307-10
31. Remick J, Georgiopoulou V, Marti C, Ofotokun I, Kalogeropoulos A, Lewis W, et al. Heart Failure in Patients with Human Immunodeficiency Virus Infection: Epidemiology, Pathophysiology, Treatment, and Future Research. *Circulation* 2014; 129:1781-9
32. Ingels NB, Daughters GT, Baan J. Systolic and diastolic function of the heart: Ios Press; 1996.
33. Idris NS, Cheung MMH, Grobbee DE, Burgner D, Kurniati N, Uiterwaal CSPM. Cardiac Effects of Antiretroviral-Naïve versus Antiretroviral-Exposed HIV Infection in Children. *PLoS ONE* 2016; 11:e0146753
34. Patel DA, Lavie CJ, Milani RV, Shah S, Gilliland Y. Clinical Implications of Left Atrial Enlargement: A Review. *The Ochsner Journal* 2009; 9:191-6
35. Nadruz W, Shah AM, Solomon SD. Diastolic Dysfunction and Hypertension. *Medical Clinics of North America* 2017; 101:7-17
36. Chatterton-Kirchmeier S, Camacho-Gonzalez AF, McCracken CE, Chakraborty R, Batsky DL. Increased Prevalence of Elevated Blood Pressures in HIV-Infected Children, Adolescents and Young Adults. *The Pediatric infectious disease journal* 2015; 34:610-4
37. Jobe M, Agbla SC, Prentice AM, Hennig BJ. High blood pressure and associated risk factors as indicator of preclinical hypertension in rural West Africa: A focus on children and adolescents in The Gambia. *Medicine* 2017; 96
38. Kagura J, Adair LS, Musa MG, Pettifor JM, Norris SA. Blood pressure tracking in urban black South African children: birth to twenty cohort. *BMC Pediatrics* 2015; 15:78
39. Mbolla E, Fikahem B, Okoko AR, Babela M, Robert J, Ekouya Bowassa G, et al. Prehypertension and hypertension among schoolchildren in Brazzaville, Congo. *International journal of hypertension* 2014; 2014
40. Daniel G, Amusa L, Mhlongo D, Khoza L, Anyanwu F. Elevated blood pressure among rural South African children in Thohoyandou, South Africa. *Iranian journal of public health* 2013; 42:489
41. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology. *Journal of the American Society of Echocardiography* 2005; 18:1440-63
42. Huwez FU, Houston AB, Watson J, McLaughlin S, Macfarlane PW. Age and body surface area related normal upper and lower limits of M mode echocardiographic measurements and left ventricular volume and mass from infancy to early adulthood. *British Heart Journal* 1994; 72:276-80
43. Voelkel NF, Quaife RA, Leinwand LA, Barst RJ, McGoon MD, Meldrum DR, et al. Right Ventricular Function and Failure: Report of a National Heart, Lung, and Blood Institute Working Group on Cellular and Molecular Mechanisms of Right Heart Failure. *Circulation* 2006; 114:1883-91
44. Cohn JN. Structural basis for heart failure. Ventricular remodeling and its pharmacological inhibition. *Circulation* 1995; 91:2504-7
45. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Levy D. Left Ventricular Dilatation and the Risk of Congestive Heart Failure in People without Myocardial Infarction. *New England Journal of Medicine* 1997; 336:1350-5
46. Jone P-N, Dunbar Ivy D. Echocardiography in pediatric pulmonary hypertension. *Frontiers in Pediatrics* 2014; 2
47. Groh GK, Levy PT, Holland MR, Murphy JJ, Sekarski TJ, Myers CL, et al. Doppler echocardiography inaccurately estimates right ventricular pressure in children with elevated right heart pressure. *J Am Soc Echocardiogr* 2014; 27:163-71
48. Barbarini G, Barbaro G. Incidence of the involvement of the cardiovascular system in HIV infection. *Aids* 2003; 17:S46-S50
49. Bella SD, Grilli E, Cataldo MA, Petrosillo N. Selenium Deficiency and HIV Infection. *Infectious Disease Reports* 2010; 2:e18
| Variable                                      | N (%) unless otherwise stated |
|----------------------------------------------|--------------------------------|
| **Female**                                   | 92 (46)                        |
| Age, years (median, IQR)                     | 11.1 (9 – 12)                  |
| Age at HIV diagnosis, years (median, IQR)    | 5.1 (3-7)                      |
| CD4, cell/μl (median, IQR)                   | 726 (473-935)                  |
| Viral load <400 copies/ml                    | 154 (78)                       |
| Duration on ART, y (median, IQR)             | 4.7 (2.6-6.4)                  |
| Age at ART initiation, y (median, IQR)       | 6 (3-8)                        |
| Treated for TB                               | 74 (37)                        |
| **ART-Regimen**                              |                                |
| 2NRTIs + PI n                                | 40 (19.9)                      |
| 2NRTIs + NNRTI n                             | 154 (76.6)                     |
| Unknown n                                    | 7 (3.5)                        |
| **Antiretroviral drugs**§                    |                                |
| Zidovudine                                   | 105 (52)                       |
| Nevirapine                                   | 103 (51)                       |
| **Symptoms and signs**                       |                                |
| Chest pains on exertion                      | 34 (17)                        |
| Dizziness                                    | 19 (9)                         |
| Tachycardia at rest                          | 13 (6.5)                       |
| Tachypnoea                                   | 14 (7.2)                       |
| Hypoxia*                                     | 24 (12)                        |
| Chronic cough                                | 30 (15)                        |
| Abnormal spirometry                          | 42 (24)                        |
| Ankle swelling                               | 4 (2)                          |
| Wasting                                      | 44 (22)                        |
| Condition                                | Count (Percentage) |
|------------------------------------------|--------------------|
| Stunting                                 | 48 (24)            |
| NYHA functional class >1                 | 36 (18)            |
| Abnormal Blood Pressure †                | 106 (54)           |
| Pre-hypertension                         | 21 (20)            |
| Hypertension                             | 85 (80)            |
| High fasting glucose (>7) ‡              | 2 (1)              |

Abbreviations: ART, antiretroviral therapy; NRTI, nucleoside reverse transcriptase; NNRTI, non-nucleoside reverse transcriptase; NYHA, New York heart association; IQR, interquartile range

*missing data on n=3; †missing data on n=4; ‡missing data on n=7; § antiretroviral drugs evaluated in the logistic regression model
Table 2: Echocardiographic measures

| Measurement                          | N=197  |
|-------------------------------------|--------|
|                                    | Median (IQR) |
| Body surface area (m²)              | 1.03 (0.92-1.15) |
| LV diameter z-score                 | 0.68 (-0.22-1.25) |
| IVS diameter z-score                | 0.09 (0.66-0.80) |
| LV posterior wall z-score           | 0.28 (-0.51-1.07) |
| Left atrium diameter z-score        | 0.32 (-0.44-1.20) |
| Fractional shortening (%)           | 31 (5.2) * |
| Ejection Fraction (%)               | 62 (6.6) * |
| E wave (m/s)                        | 0.91 (0.81-1.02) |
| A wave (m/s)                        | 0.53 (0.47-0.60) |
| E/A ratio                           | 1.70 (1.50-1.99) |
| Deceleration Time (ms)              | 173 (156-190) |
| PV S wave (m/s)                     | 0.49 (0.41-0.56) |
| PV D wave (m/s)                     | 0.50 (0.46-0.57) |
| PV A wave (m/s)                     | 0.18 (0.16-0.21) |
| PV S/D ratio                        | 0.96 (0.79-1.16) |
| RV diameter, z-score                | 0.37 (-0.52-1.28) |
| PASP, mmHg                           | 12.8 (8.7-16.9) |
| TAPSE, z-score                      | -0.73 (-1.44-0.09) |

LV, left ventricle; IVS, interventricular septum, E/A ratio, mitral valve peak early to late left ventricular filling velocity; PV, pulmonary venous; S, systolic; D, diastolic; PASP, pulmonary arterial systolic pressure; TAPSE, tricuspid annular plane systolic excursion; * mean (SD)
Table 3: Proportions of cardiac abnormalities

| Abnormalities                  | Local references* [18] | European references [19] |
|--------------------------------|------------------------|--------------------------|
|                                | N=197                  | N=197                    |
|                                | N (%)                  | N (%)                    |
| LV dilatation                  | 9 (5)                  | 9 (5)                    |
| LVH                            | 22 (11)                | 73 (37)                  |
| - Interventricular septal hypertrophy | 2 (9)                | 52 (71)                  |
| - Posterior wall hypertrophy   | 20 (91)                | 4 (6)                    |
| - Concentric hypertrophy       | -                      | 17 (23)                  |
| Left atrial dilatation         | 16 (8)                 | 12 (6)                   |
| LV systolic dysfunction        | 3 (2)                  | 3 (2)                    |
| LV diastolic dysfunction       | 45 (23)                | 45 (23)                  |
| RV dilatation                  | 13 (7)                 | 57 (29)                  |
| RV systolic dysfunction        | 4 (2)                  | -                        |
| Any echocardiographic abnormality | 83 (42)               |                          |
| Any left heart abnormality     | 77 (39)                |                          |
| Any right heart abnormality    | 15 (8)                 |                          |

*, local reference ranges were used as the primary basis of defining cardiac abnormalities.

Abbreviations: LA, left atrium; LV, left ventricle; LVH, left ventricular hypertrophy; RV, right ventricular
missing data on n=4
Table 4: Factors associated with left heart abnormalities

| Variable                      | LV Diastolic Dysfunction                  |          | LVH                  |          |
|-------------------------------|------------------------------------------|----------|----------------------|----------|
|                               | Prevalence Unadjusted | Adjusted | Prevalence Unadjusted | Adjusted |
|                               | n/N (%) OR (95% CI) p-value | OR (95% CI) P-value | n/N (%) OR (95% CI) P-value | OR (95% CI) P-value |
| Sex                           |                           |          |                      |          |
| Female                        | 20/94 (21) 1              |          | 14/94 (15) 1         |          |
| Male                          | 25/103 (24) 0.19 (0.16-2.31) 0.61 |          | 8/103 (8) 0.48 (0.12-1.21) 0.12 |          |
| Age                           |                           |          |                      |          |
| 6-10 years                    | 25/91 (27) 1              |          | 10/91 (11) 1         |          |
| 11-16 years                   | 20/106 (19) 0.61 (0.31-1.20) 0.15 |          | 12/106 (11) 1.03 (0.42-2.52) 0.94 |          |
| Age at ART initiation         |                           |          |                      |          |
| 0-5 years                     | 27/93 (29) 1.91 (0.93-3.90) 0.08 |          | 13/93 (14) 2.14 (0.77-5.91) 0.14 |          |
| 6-10 years                    | 15/85 (18) 1              |          | 6/85 (7) 1           |          |
| 11-16 years                   | 3/17 (18) 1.00 (0.26-3.92) 1 |          | 3/17 (18) 2.82 (0.63-12.6) 0.18 |          |
| Duration on ART              |                           |          |                      |          |
| ≤ 2 years                     | 10/55 (18) 1              |          | 6/55 (11) 1          |          |
| > 2 years                     | 35/142 (25) 1.47 (0.67-3.22) 0.33 |          | 16/142 (11) 1.04 (0.38-2.80) 0.94 |          |
| CD4 count                     |                           |          |                      |          |
| > 200 cell/μl                 | 44/187 (24) 1             |          | 21/187 (11) 1       |          |
| ≤ 200 cell/μl                 | 1/9 (11) 0.41 (0.05-3.34) 0.40 |          | 1/9 (11) 0.99 (0.12-8.30) 0.99 |          |
| Viral load                    |                           |          |                      |          |
|                    | No       | Yes                       | 95% CI       | p-value |
|-------------------|----------|---------------------------|--------------|---------|
| ≤400 copies/ml    | 35/152 (23)  | 18/152 (12)               | 1            |         |
| >400 copies/ml    | 9/41 (22)  | 3/41 (7)                  | 1.70 (0.48-6.08)  | 0.41    |
| Nevirapine *      |           |                           |              |         |
| No                | 22/98 (22) | 6/98 (6)                  | 1            |         |
| Yes               | 23/99 (23) | 16/99 (16)                | 2.96 (1.10-7.91)  | 0.03    |
| Zidovudine*       |           |                           |              |         |
| No                | 17/95 (18) | 8/95 (8)                  | 1            |         |
| Yes               | 28/102 (27) | 14/102 (14)               | 1.73 (0.69-4.33)  | 0.242   |
| Cardiac symptoms† |           |                           |              |         |
| No                | 27/119 (23) | 13/119 (10)               | 1            |         |
| Yes               | 18/78 (23) | 9/78 (12)                 | 1.06 (0.43-2.62)  | 0.89    |
| Hypertension      |           |                           |              |         |
| No                | 12/92 (13) | 12/92 (13)                | 1            |         |
| Yes               | 33/103 (32) | 10/103 (10)               | 0.72 (0.29-1.75)  | 0.46    |

ART, antiretroviral therapy; LV, left ventricular; LVH, left ventricular hypertrophy * Antiretroviral drugs; † cardiac signs and symptoms included hypoxia, chest pains, tachypnoea, and ankle swelling
Figure 1: Participant Recruitment

HIV+ Screened
N=921

341 Unaccompanied by guardian
32 Not residing in Harare
51 no consent
59 Not on ART
39 On ART <6 months
2 TB treatment <8 weeks

Eligible for recruitment
N=397

195: not recruited because the first 5 had already been taken

Recruited
202

1 Withdraw

Study procedures
197 Echocardiography
197 Clinical assessment
200 CD4 count
199 Viral load
200 spirometry (n=177 met QC criteria)
Supplementary Figure 1: Bland-Altman plots for intra- and interobserver agreement for cardiac measures

A: Intra-observer agreement Bland-Altman plots

B: Inter-observer agreement plots
Supplementary Table 1: Factors associated with enrolment in the study

| Variable                        | Enrolled N=200 | Not enrolled N=197 | Test coefficient, p-value |
|---------------------------------|----------------|--------------------|---------------------------|
| Age, y, mean (SD)               | 10.5 (2.5)     | 9.9 (2.7)          | \( t = -2.20, p = 0.03 \) |
| Sex, n (%) female              | 96 (48.0)      | 86 (43.7)          | \( \chi^2 = 0.75, p = 0.39 \) |
| Taking TB treatment, n (%)      | 1 (0.5)        | 1 (0.5)            | \( \chi^2 = 0.00, p = 0.99 \) |
| Age at ART initiation, y, mean (SD) | 6.1 (3.2)     | 5.1 (3.3)          | \( t = -3.04, p = 0.003 \) |

SD, standard deviation; TB, tuberculosis; ART, antiretroviral therapy
**Supplementary Table 2: Factors associated with RV abnormalities**

| Variable                          | RV abnormalities | Prevalence | Unadjusted          | P-value |
|-----------------------------------|------------------|------------|---------------------|---------|
|                                   |                  | n/N (%)    | OR (95% CI)         |         |
| **Sex**                           |                  |            |                     |         |
| Female                            | 9/94 (9)         | 1          |                     |         |
| Male                              | 6/103 (5)        | 0.58 (0.20 - 1.71) | 0.33 |
| **Age**                           |                  |            |                     |         |
| 6-10 years                        | 6/91 (7)         | 1          |                     |         |
| 11-16 years                       | 9/106 (8)        | 1.31 (0.45 - 3.84) | 0.50 |
| **Age at ART initiation**         |                  |            |                     |         |
| 0-5 years                         | 6/93 (6)         | 0.77 (0.25-2.38) | 0.65 |
| 6-10 years                        | 7/85 (8)         | 1          |                     |         |
| 11-16 years                       | 2/17 (12)        | 1.49 (0.28-7.86) | 0.64 |
| **Duration on ART**               |                  |            |                     |         |
| ≤2 years                          | 5/55 (9)         | 1          |                     |         |
| >2 years                          | 10/142 (7)       | 0.80 (0.28-2.30) | 0.6   |
| **CD4 count**                     |                  |            |                     |         |
| >200 cell/μl                      | 14/187 (7)       | 1          |                     |         |
| ≤200 cell/μl                      | 0                | -          |                     | -       |
| **Viral load**                    |                  |            |                     |         |
| ≤400 copies/ml                    | 15/152 (10)      | 1          |                     |         |
| >400 copies/ml                    | 0                | -          |                     | -       |
| **Nevirapine**                    |                  |            |                     |         |
| No                                | 9/98 (9)         | 1          |                     |         |
| Yes                               | 6/99 (6)         | 0.64 (0.22-1.87) | 0.41 |
| **Zidovudine**                    |                  |            |                     |         |
| No                                | 8/95 (8)         | 1          |                     |         |
| Yes                               | 7/102 (7)        | 0.80 (0.28-2.30) | 0.68 |
| Condition                  | No     | Yes         | Odds Ratio (95% CI) | P       |
|----------------------------|--------|-------------|---------------------|---------|
| **Cardiac symptoms†**      |        |             |                     |         |
| No                         | 9/119 (8) | 1           |                     |         |
| Yes                        | 6/78 (8)  | 1.02 (0.35-2.98) | 0.97                |         |
| **Hypertension**           |        |             |                     |         |
| No                         | 8/92 (9)  | 1           |                     |         |
| Yes                        | 7/103 (7) | 0.77 (0.27-2.20) | 0.62                |         |
| **Chronic lung disease**   |        |             |                     |         |
| No                         | 10/121 (8) | 1           |                     |         |
| Yes                        | 5/76 (7)   | 0.78 (0.26-2.38) | 0.67                |         |

*ART, antiretroviral therapy; RV, right ventricular; *Antiretroviral drugs; †cardiac signs and symptoms included hypoxia, chest pains, tachypnoea, and ankle swelling